Cyclo Therapeutics (CYTH)

Take Impact Assessment
Overall impact
C (58)

Commentary

Cyclo Therapeutics is an average overall performer. With a 'C' rating of 58.0 for overall impact (58th percentile compared to all companies), Cyclo Therapeutics ranks 37th out of 151 industry peers, behind Northern Technologies International, Gulf Resources, Ingevity and 33 others, and ahead of Amyris, Aemetis, Kraton and 111 others. On top material causes for Cyclo Therapeutics's industry (Chemicals), Cyclo Therapeutics performs well in Reduced Waste (95.3 score), Child and Maternal Health (87.0) and Humane Treatment of Animals (81.1) and performs poorly in Reduced Green House Gas Emissions (12.3 score).
... read full commentary
Less
Screens
Advertising
Alcohol
Alcohol - responsible marketing
Animal treatment
Anti-abortion support
Anti-Israel
Anti-personnel mines
Anti-social publishing
Arctic drilling
Banned pesticides and chemicals
Biological and chemical weapons
Cannabis
Carbon emissions intensity
Child safety
Cluster munitions
Coal
Conflict minerals
Contraceptives
Controversial weapons
Deforestation - financing
Deforestation - supply chain
Depleted uranium
Discrimination controversies
Electrical utility
Endangered wildlife
Environmental controversies
EU sanctions list
Factory farming
Fast food
Firearms
Food commodity derivatives
For-profit health care
Fossil fuel
Fur
Gambling
Genetic engineering
Health-related controversies
Human rights controversies
Human trafficking
ILO Conventions
Interest-based products
Interest-bearing debt
Interest-bearing securities
Iran
Land use and biodiversity
Military contracting
Misleading communication
Modern slavery
Music
Myanmar
Non-sustainable palm oil
Norges Bank exclusion list
Northern Ireland (Macbride)
North Korea
No SBTI commitment
Nuclear
OECD Guidelines
Oil and gas
Opioid controversies
Oppressive governments
Palestinian human rights
Pharma controversies
Pork
Pornography
Predatory lending
Prison involvement
Privacy breaches
Pro-life
Russia
Single-use plastic
Stem cell research
Sudan
Sugar
Syria
Tar sands
Thermal coal
Tobacco
Tobacco - GICS
UK sanctions list
Undermining US elections
UN Global Compact
UN Guiding Principles
US OFAC sanctions list
Weapons
Impact
Cause CYTH
Peer rank
Overall impact

Log in to view this information

Screens
Advertising
Alcohol
Alcohol - responsible marketing
Animal treatment
Anti-abortion support
Anti-Israel
Anti-personnel mines
Anti-social publishing
Arctic drilling
Banned pesticides and chemicals
Biological and chemical weapons
Cannabis
Carbon emissions intensity
Child safety
Cluster munitions
Coal
Conflict minerals
Contraceptives
Controversial weapons
Deforestation - financing
Deforestation - supply chain
Depleted uranium
Discrimination controversies
Electrical utility
Endangered wildlife
Environmental controversies
EU sanctions list
Factory farming
Fast food
Firearms
Food commodity derivatives
For-profit health care
Fossil fuel
Fur
Gambling
Genetic engineering
Health-related controversies
Human rights controversies
Human trafficking
ILO Conventions
Interest-based products
Interest-bearing debt
Interest-bearing securities
Iran
Land use and biodiversity
Military contracting
Misleading communication
Modern slavery
Music
Myanmar
Non-sustainable palm oil
Norges Bank exclusion list
Northern Ireland (Macbride)
North Korea
No SBTI commitment
Nuclear
OECD Guidelines
Oil and gas
Opioid controversies
Oppressive governments
Palestinian human rights
Pharma controversies
Pork
Pornography
Predatory lending
Prison involvement
Privacy breaches
Pro-life
Russia
Single-use plastic
Stem cell research
Sudan
Sugar
Syria
Tar sands
Thermal coal
Tobacco
Tobacco - GICS
UK sanctions list
Undermining US elections
UN Global Compact
UN Guiding Principles
US OFAC sanctions list
Weapons
Impact trend

Change in rating for overall impact

Log in to view this information

Company
Employees
8
Sector
Materials
Industry
Chemicals
Sub-industry
Specialty Chemicals
SASB industry
Chemicals
Headquarters
Fl, United States
Share classes
CYTH
More info
https://cyclotherapeutics.com
Description
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is headquartered in Gainesville, Florida. Cyclo Therapeutics, Inc. is a subsidiary of Rafael Holdings, Inc.
Material causes
Ethos considers the following causes material for Cyclo Therapeutics, based on its industry sub-industry Specialty Chemicals. Learn more about material causes in our methodology overview.
Accountable institutions
Build accountable and inclusive institutions at all levels
Child and maternal health
End preventable deaths of mothers and children, support reproductive health everywhere
Clean water access
Ensure availability of clean, safe water for all
Decent, safe work opportunities
Promote full and productive employment for all, in safe work environments
Equal pay and opportunity
Achieve equal pay and opportunity for women everywhere
Fair labor practices
Ensure fair and humane labor practices everywhere
Healthy oceans
Support healthy oceans and marine biodiversity, including through reduced pollution
Humane treatment of animals
Ensure humane treatment of animals everywhere
Improved mental health
Support awareness and access to mental health support for all
LGBTQ equality
Ensure equal rights for all lesbian, lesbian, gay, bisexual, transgender and queer people
No poverty
End poverty in all its forms everywhere
Racial justice and civil rights
Eliminate racism and ensure justice for all
Reduced green house gas emissions
Continually reduce green house gas emissions and other pollutants
Reduced inequality
Reduce inequality within and among countries
Reduced waste
Reduce waste and support re-usable materials
Sanitation access
Ensure availability of basic sanitation for all
Sustainable use of natural resources
Ensure sustainable use of natural resources
Sustainable use of water
Promote sustainable management of water everywhere
Terrestrial biodiversity
Protect biodiversity and wildlife habitats on land, preserve forests and combat land degradation
Peace and justice
Promote peaceful and inclusive societies, provide access to justice for all
Health and well-being
Ensure healthy lives and promote well-being for all at all ages
Water and sanitation
Ensure availability and sustainable management of water and sanitation for all
Inclusive economies
Create inclusive economies with no poverty, decent work for all, and affordable living conditions
Gender equality
Achieve gender equality and empower all women and girls
Life on earth
Protect biodiversity and ensure sustainable use of ecosystems
Climate action
Take urgent action to combat climate change and its impacts
Sustainable resource use
Ensure sustainable consumption and production patterns

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.
OK
OK, I agree
No thanks